Flucloxacillin Dosing for Hospitalized Adults with LRTI Due to Penicillinase-Producing Staphylococcus aureus
For hospitalized adults with lower respiratory tract infection caused by penicillinase-producing (methicillin-susceptible) Staphylococcus aureus, flucloxacillin should be administered at 2 grams IV every 6 hours (8 grams total daily dose). 1
Rationale for Dosing
The recommended regimen is based on established guidelines for hospital-acquired pneumonia (HAP) when methicillin-susceptible S. aureus (MSSA) is the confirmed or suspected pathogen:
Standard empiric dosing for MSSA coverage in HAP includes piperacillin-tazobactam 4.5g IV q6h, cefepime 2g IV q8h, or carbapenems, but when MSSA is confirmed, antistaphylococcal penicillins like flucloxacillin become preferred agents 1
Flucloxacillin 2g IV every 6 hours (total 8g/day) represents the standard high-dose regimen for serious staphylococcal infections including respiratory tract infections 2, 3
For severe or complicated infections, doses up to 12 grams daily (3g IV q6h) may be necessary, particularly in critically ill patients or those with deep-seated infections 4, 5
Key Clinical Considerations
Therapeutic Drug Monitoring
Standard dosing may be inadequate in approximately 26% of patients, particularly those who are younger or have augmented renal clearance 6
Measuring unbound flucloxacillin concentrations is valuable for dose optimization, with target concentrations of ≥1-2 times the MIC (typically 0.5 mg/L for MSSA) 6
Continuous infusion (8-12g/24h) may be superior to intermittent bolus dosing for maintaining therapeutic concentrations, achieving serum levels of 8-40 mg/L 5
Common Pitfalls and Monitoring
Hypokalaemia occurs in 42% of patients receiving IV flucloxacillin, requiring standardized potassium monitoring and replacement 7
Women are more prone to developing hypokalaemia than men during flucloxacillin therapy 7
In critically ill patients with hypoalbuminemia or augmented renal clearance, standard dosing frequently results in subtherapeutic levels 4
Alternative Considerations
Cefazolin (2g IV q8h) is an alternative with similar efficacy but significantly better tolerability profile, with fewer discontinuations due to adverse events (13% discontinuation rate with flucloxacillin vs minimal with cefazolin) 8
If MRSA cannot be excluded initially, empiric coverage should include vancomycin 15 mg/kg IV q8-12h (targeting trough 15-20 mg/mL) or linezolid 600 mg IV q12h, then de-escalate to flucloxacillin once MSSA is confirmed 1
Duration and Source Control
Treatment duration for MSSA bacteremia with respiratory source typically requires minimum 2 weeks, extended to 4-6 weeks if complicated by endocarditis, osteomyelitis, or metastatic foci 2, 3
Identify and address any source control issues including removal of infected devices or drainage of collections 3